Interestingly, the cisplatin sensitivity of cancer cell lines expressing BIN1+12A, an aberrant alternative splicing variant of BIN1 [24], was unchanged by sh-BIN1 (Figure 1B), suggesting that the impairment of wt-BIN1 by a BIN1 loss or aberrant alternative splicing abolishes the cisplatin sensitivity regardless of the TP53 gene expression status. The gene discussed is BIN1; the disease is cancer.